Aoyama Zaisan Networks Company,Limited Logo

Aoyama Zaisan Networks Company,Limited

Consulting on inheritance and business succession for individuals and corporations.

8929 | T

Overview

Corporate Details

ISIN(s):
JP3825750007
LEI:
Country:
Japan
Address:
港区赤坂八丁目4番14号青山タワープレイス3階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Aoyama Zaisan Networks Company, Limited is a Japanese consulting firm specializing in comprehensive property and asset management solutions. The company primarily offers two types of services: inheritance consulting for individual asset owners and business succession consulting for corporations. It leverages its expertise in real estate, financial products, and related services to provide tailored solutions for asset transfer, maintenance, and operations. The firm's service portfolio also includes real estate solutions and property investment support in the USA.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-07 08:32
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-08-07 08:31
Interim Report
半期報告書-第35期(2025/01/01-2025/12/31)
Japanese 201.7 KB
2025-06-11 06:18
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.3 KB
2025-05-09 05:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2025-04-07 03:24
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2025-03-27 07:51
Registration Form
確認書
Japanese 8.2 KB
2025-03-27 07:51
Governance Information
内部統制報告書-第34期(2024/01/01-2024/12/31)
Japanese 22.0 KB
2025-03-27 07:50
Annual Report
有価証券報告書-第34期(2024/01/01-2024/12/31)
Japanese 2.0 MB
2025-03-27 07:46
Post-Annual General Meeting Information
臨時報告書
Japanese 23.4 KB
2025-03-10 08:44
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2025-02-10 07:56
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2025-01-15 08:52
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.1 KB
2024-12-12 06:15
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.9 KB
2024-11-14 08:01
M&A Activity
臨時報告書
Japanese 64.0 KB
2024-08-08 08:03
Report Publication Announcement
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all Aoyama Zaisan Networks Company,Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aoyama Zaisan Networks Company,Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aoyama Zaisan Networks Company,Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan
4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150

Talk to a Data Expert

Have a question? We'll get back to you promptly.